

## DAFTAR PUSTAKA

- Abbas, A. K., Lichtman, A. H. & Pober, J. S. 2000 Cellular and molecular immunology. Fourth Edition. Philadelphia, WB Saunders Company.
- Baldwin, H. E. 2002 The Interaction Between Acne Vulgaris and the psyche. *Cutis*. 70: 133-9.
- Ballanger, F., Baudry, P., Guyen, J. M., Khammari, A. & Dreno, B. 2006 Heredity: A Prognostic Factor for Acne. *Dermatology*. 212: 145-9.
- Baran, R., Chivot, M., Shalita, A., Lewis, A. & Wechsler, A. 2005 Acne. IN Baran, R. & Maibach, H. (Eds.) *Textbook of Cosmetic Dermatology*. London, Taylor & Francis.
- Blumenberg, M., Komine, M., Rao, L. 1998 Blueprint to footprint to toeprint to culprit: regulation of K6 keratin gene promoter by extracellular signals and nuclear transcription factors. *J Invest Dermatol* 110: 495.
- Bratawidjaja, K. G. 2000 Imunologi dasar. Jakarta Balai Penerbit Fakultas Kedokteran Universitas Indonesia
- Burkhart, C. N. 2003 Clinical Assessment of Acne Pathogenesis with Treatment Implications. *International Pediatrics*. 18: 14-9.
- Burns, T., Stephen, B. & 2010 Disorders of Sebaceous Glands. *Rookos Textbook of Dermatology. Edisi 8*. Oxford, Wiley-Blackwell.
- Collier, C. N., Harper, J. C., Cafardi, J. A. 2008 The Prevalence of Acne in Adults 20 years and older *J Am Acad Dermatol*. 58: 56-9.
- Cordain, L. 2005 Implications for the role of diet in acne. *Semin Cutan Med Surg*. 24: 84-91.
- Cotterill, J. A. & Cunliffe, W. J. 1997 Suicide in dermatological patients. *Br J Dermatol*. 137: 246-50.
- Cunliffe, W. J., Holland, D. B. & Jeremy, A. 2004 Comedone Formation: Etiology, Clinical Presentation, and Treatment. *Clinics in Dermatology*. 2004: 367-74.
- Cunliffe, W. J. & Gollnick, H., (BOEK) 2001 Acne: Diagnosis and Management. *London: Martin Dunitz Ltd*. 15.

- Cunliffe, W. J., Holland, D. B., Clark, S. M. & Stables, G. I. 2003 Comedogenesis: Some aetiological, Clinical and Therapeutic Strategies. *Dermatology* 206: 11-6.
- Cunliffe, W. J., Perera, D. H., Thackeray, P., Williams, M., Froster, R. A. & Williams, S. M. 2007 Pilo Sebaceous duct physiology, observation on the number and size of pilo sebaceous ducts in acne vulgaris. *J Dermatol.* 95.
- Do, T., Zarkhin, S., Orringer, J. S. & Nemeth, S. 2008 Computer-assisted Alignment and Tracking of Acne Lesion Indicate That Most Inflammatory Lesions Arise from Comedones and de novo. *J Am Acad Dermatol.* 603-8.
- Downing, D. T., Stewart, M. E., Wertz, P. W. 1986 Essential fatty acids and acne. *J Am Acad Dermatol* 14: 221-5.
- Farrar, M. D. & Ingham, E. 2004 Acne: Inflammation. *Clinics in Dermatology.* 22: 380-4.
- Ferdowsian, H. R. & Levin, S. 2010 Does Diet Really Affect Acne? *Skin Therapy Letter.* 15: 4-5.
- Gollnick, H. & Cunliffe, W. 2003 Management of Acne a report from a global alliance to improve outcomes in acne. *J Am Acad Dermatol.* 49: S1-38.
- Goodman, G. J. 2000 Postacne scarring: a review of its pathophysiology and treatment. *Dermatol Surg.* 26: 857-71.
- Goodman, G. J. 2001 Post-acne scarring: a short review of its pathophysiology. *Australas J Dermatol.* 42: 84-90.
- Goulden, V., Glass, D. & Cunliffe, W. J. 1999a Safety of long term high dose minocycline in the treatment of acne. *Br J Dermatol.* 134: 693-5.
- Goulden, V., Stables, G. I. & Cunliffe, W. J. 1999b Prevalence of facial acne in adults. *J Am Acad Dermatol.* 41: 577-80.
- Guy, R., Green, M. R. & Kealey, T. 1996 Modeling Acne in Vitro. *J Invest Dermatol.* 106: 176-182.
- Guy, R. & Kealey, T. 1998a The effects of inflammatory cytokines on the isolated human sebaceous infundibulum. *J Invest Dermatol* 110: 410-5.

- Guy, R. & Kealey, T. 1998b Modeling the infundibulum in acne. *Dermatology*. 196: 32-7.
- Heughebaert, C. & Shalita, A. 2011 Comedogenesis. dalam Shalita, A., Rosso, J. & Webster, G. F. (Eds.) *Acne Vulgaris*. New York, Informa Healthcare.
- Hirsch, R. J. & Lewis, A. B. 2001 Treatment of acne scarring. *Semin Cutan Med Surg*. 20: 190-8.
- Holland, D. B., Jeremy, A. H. T., Roberts, S. G., Seukeran, D. C., Layton, A. M. & Cunliffe, W. J. 2004 Inflammation in acne scarring: a comparison of the responses in lesions from patients prone and not prone to scar. *Br J Dermatol*. 150: 72-81.
- Ingham, E., Eady, E. A., Goodwin, C. E. 1992 Pro inflammatory levels of interleukin 1 alpha like bioactivity are present in the majority of open comedones in acne vulgaris. *J Invest Dermatol*. 98: 895 - 901.
- Jeremy, A., Holland, D. B., Roberts, S. G., Thomson, K. F. & Cunliffe, W. J. 2003 Inflammatory Events Are Involved in Acne Lesion Initiation. *J Invest Dermatol*. 121: 20-7.
- Jiang, C. K., Flanagan, S., Ohtsuki, M. 1994 Disease activated transcription factor: allergic reactions in human skin cause nuclear translocation of STAT 91 and induce synthesis of keratin 17. *Mol Cell Biol*. 14: 4759-69.
- Jiang, C. K., Magnaldo, T., Ohtsuki, M. 1993 Epidermal growth factor and transforming growth factor a specifically induce the activation and hyperproliferation associated keratins 6 and 16. *Proc Natl Acad Sci U S A* 90: 6786-90.
- Kealey, T. & Guy, R. 1997 Modeling the infundibulum in acne. *J Am Acad Dermatol*. 108: 376. 108: 376.
- Kim, J. 2005 Review of the innate immune response in acne vulgaris: activation of Toll like receptor 2 in acne triggers inflammatory cytokine responses. *Dermatology*. 211: 193-8.
- Koreck, A., Pivarcsi, A., Dobozy, A. & Kemeny, L. 2003 The Role of Innate Immunity in the Pathogenesis of Acne. *Dermatology*. 206: 96 -105.
- Kresno, S. M. 1996 *Imunologi : Diagnosis dan Prosedur Laboratorium*. Jakarta, Balai Penerbit Fakultas Kedokteran Universitas Indonesia.

- Krishna, S., Kim, C. & kim, J. 2011 Innate Immunity in The Pathogenesis of Acne Vulgaris. IN Shalita, A., Rosso, J. & Webster, G. F. (Eds.) New York, Informa Healthcare.
- Layton, A. M., Henderson, C. A. & Cunliffe, W. J. 1994 A clinical evaluation of acne scarring and its incidence. *Clin Exp Dermatol.* 19: 303-8.
- Leeming, J. P., Holland, K. T. & Cunliffe, W. J. 1985 The pathological and exological significance of microorganisms colonizing acne vulgaris comedones. *J Med Microbiol.* 20: 11-6.
- Letawe, C., Boone, M. & Pierard, G. E. 1998 Digital image analysis of the effect of topically applied linoleic acid on acne microcomedones. *Clin Exp Dermatol.* 23.
- Leyden, J. J., McGinley, K. J. & Vowels, B. 1998 Propionibacterium acnes colonization in acne and nonacne. *Dermatology.* 1998: 55-8.
- Liao, D. J. 2003 Management of acne. *The Journal of Family Practice.* 52: 43-51.
- Loveckova, Y. & Havlikovab, I. 2002 A Microbiological approach to Acne vulgaris. *Biomed Papers.* 146: 29-32.
- Motoyoshi, K. 1983 Enhanced comedo formation in rabbit ear skin by squalene and oleic acid peroxides. *Br J Dermatol.* 109: 191-8.
- Nahidi, Y., Javidi, Z., Shakeri, M. T. & Farrokhnezhad, S. 2012 Does cigarette smoking influence acne? *Iran J Dermatol.* 15: 80-4.
- Nouri, K., Lanigan, S. W. & Rivas, M. P. 2005 Laser treatment for scars. dalam Goldberg, D. J. (Ed.) *Laser and lights.* Philadelphia, Elsevier Saunders.
- Perisho, K., Wertz, P. W., Madison, K. C. 1988 Fatty acids of acylceramides from comedones and from the skin surface of acne patients and control subjects. *J Invest Dermatol.* 90: 350-3.
- Pierard, G. E., Pierard-Franchimont, C., Goffin, V. 1995 Digital image analysis of microcomedones. *Dermatology* 190.
- Pochi, P. E. & Strauss, J. S. 1994 Endocrinologic control of the development and activity of the human sebaceous gland. *J Invest Dermatol.* 62: 191-201.

- Rivera, A. E. & Spencer, J. M. 2007 Clinical aspects of full thickness wound healing. *Clin Dermatol.* 25: 39-48.
- Simpson, N. & Cunliffe, W. 2007 Disorders of the sebaceous glands IN Bums, T., Breathnach, S., Cox, N. & Griffiths, C. (Eds.) *Rook's textbook of dermatology.* . Massachusetts, Blackwell Science.
- Siregar, R. S. 2003 Akne Vulgaris. dalam Carolin, w. & Peter, A. (Eds.) *Atlas Berwarna Sariwati Penyakit Kulit, Cetakan III,*. Jakarta, EGC.
- Smith, R., Mann, N., Braue, A., Makelainen, H. & Varigos, G. 2007 A low-glycemic-load diet improves symptoms in acne vulgaris patients: a randomized controlled trial. *American Journal of Clinical Nutrition.* 86: 107-115.
- Smith, R. N., Braue, A., Varigos, G. A. 2008 The effect of a low glycemic load diet on acne vulgaris and the fatty acid composition of skin surface triglycerides. *J Dermatol Sci.* 50: 41-52.
- Suh, D. H., Kwon, T. H. & Youn, J. I. 2002 Changes of comedonal cytokines and sebum secretion after UV irradiation in acne patients. *European Journal of Dermatology.* 12: 139-44.
- Thiboutot, D., Gollnick, H., Bettoli, V. 2009 New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. *J Am Acad Dermatol.* 60: S1-S50.
- Thiboutot, D., Knaggs, H., Gilliland, K. 1998 Activity of 5 alpha reductase and 17 betahydroxysteroid dehydrogenase in the infundibulum of subjects with and without acne vulgaris. *Dermatology.* 196: 38-42.
- Thiboutot, D. M. 2000 The role of follicular hyperkeratinization in acne. *Journal of Dermatological Treatment.* 11: S5-S8.
- Tochio, T., Tanaka, H., Nakata, S. 2009 Accumulation of lipid peroxide in the content of comedones may be involved in the progression of comedogenesis and inflammatory changes in comedones. *J Cosmet Dermatol.* 8: 152-8.
- Walters, C. E., Ingham, E., Eady, E. A., Cove, J. H., Kearney, J. N. & Cunliffe, W. J. April 1995 In Vitro Modulation of Keratinocyte-Derived Interleukin-1a (IL-1a) and Peripheral Blood Mononuclear Cell-Derived IL-1b Release in Response to Cutaneous Commensal Microorganisms. *Infection and Immunity.* 63: 1223-8.

Zaenglein, A., Graber, E., Thiboutot, D. & Strauss, J. 2008 Acne vulgaris and acneiform eruptions. IN Wolff, K., Goldsmith, L., Katz, S., Gilchrest, B., Palley, A. & Leffell, D. (Eds.) *Fitzpatrick's dermatology in general medicine*. New York, Mc Graw Hill Medical.

## Lampiran 1

### FORMULIR PERSETUJUAN MENGIKUTI PENELITIAN SETELAH MENDAPAT PENJELASAN

Setelah membaca informasi penelitian serta mendengar penjelasan dan menyadari pentingnya penelitian:

#### **Kadar interleukin 1 alpha pada berbagai gradasi lesi akne vulgaris**

Saya, yang bertanda tangan dibawah ini:

Nama : \_\_\_\_\_  
Umur : \_\_\_\_\_  
Alamat : \_\_\_\_\_  
Telepon : \_\_\_\_\_

setelah mendengar/ membaca dan mengerti penjelasan yang diberikan mengenai tujuan, manfaat apa yang akan dilakukan dalam penelitian ini, bersama ini menyatakan kesediaan saya secara sukarela tanpa paksaan mengikuti penelitian ini dan mentaati semua prosedur yang akan dilakukan dalam penelitian ini.

Saya mengerti bahwa prosedur dengan cara pengambilan lesi akne vulgaris di wajah, kemungkinan bisa menimbulkan akibat yang tidak diinginkan seperti ketidaknyamanan atau infeksi namun saya yakin tindakan pemeriksaan akan dilakukan secara bebas hama dan dengan penuh kehati-hatian oleh petugas yang terlatih untuk mencegah hal-hal yang tidak diinginkan.

Saya tahu bahwa keikutsertaan saya ini bersifat sukarela tanpa paksaan, sehingga saya bisa menolak ikut atau mengundurkan diri dari penelitian ini tanpa kehilangan hak saya untuk mendapat pelayanan kesehatan. Saya juga berhak bertanya atau meminta penjelasan kepada peneliti bila masih ada hal yang belum jelas atau masih ada hal yang ingin saya ketahui tentang penelitian ini.

Saya mengerti bahwa semua biaya yang dikeluarkan sehubungan dengan penelitian ini ditanggung oleh peneliti. Demikian juga biaya perawatan dan pengobatan bila terjadi hal-hal yang tidak diinginkan akibat penelitian ini, akan dibiayai oleh peneliti.

Saya percaya bahwa keamanan dan kerahasiaan data penelitian akan terjamin dan saya dengan ini menyetujui semua data yang dihasilkan pada penelitian ini untuk disajikan dalam bentuk lisan maupun tulisan.

Bila terjadi perbedaan pendapat di kemudian hari, kami akan menyelesaikannya secara kekeluargaan.

Makassar.....2013

TGL/BLN/THN	NAMA	TANDA TANGAN
Klien	.....	.....
Saksi 1	.....	.....
Saksi 2	.....	.....

**Penanggungjawab Medis**

Nama : Dr. dr. Anis Irawan Anwar, SpKK (K)  
 Alamat : Jl Sungai Saddang Baru A11/7A, Makassar  
 Telpon : 04115012566 / 0811412678

**Penanggungjawab Peneliti**

Nama : dr. Wiwin Mulianingsih  
 Alamat : Rusunawa Unhas Cempaka 311, Makassar  
 Telpon : 04115760093 / 081353456772

<p><b>DISETUJUI</b>  <b>Komisi Etik Penelitian Kesehatan</b>  <b>FK Unhas Tgl .....</b></p>
-----------------------------------------------------------------------------------------------------



Lampiran.2

**KUESIONER PENELITIAN  
KADAR INTERLEUKIN-1 ALPHA PADA  
BERBAGAI GRADASI LESI AKNE VULGARIS**

No. Urut : \_\_\_\_\_ Makassar, ..... 2013

Nama :

Alamat :

Umur : \_\_\_\_\_ Tahun

Nomor Telp :

Jenis Kelamin :  1 Pria  2 Wanita

Pendidikan :  1 SD  2 SMP  
 3 SMA/Sederajat  4 Akademi / Sarjana  
 5 Tidak sekolah

Pekerjaan :  1 Ibu rumah tangga  2 Profesional  
 3 ABRI/Polisi  4 Pegawai negeri  
 5 Wiraswasta  6 Karyawan swasta  
 7 Lainnya

Aktivitas rutin:  1 Dalam ruangan  2 Luar ruangan

Suku :  1 Makassar  2 Bugis  
 3 Mandar  4 Toraja  
 5 Enrekang  6 Jawa  
 7 Palopo  8 Lainnya

Lingkungan kerja:  1 Stres ringan  2 Stres sedang



### Lampiran 3

#### Data sampel kadar IL-1 $\alpha$ pada lesi komedonal

Kode Sampel	Hasil			Rata-rata (pg/ml)
	A	B	C	
01	751,9504	570,8326	964,7313	762,5047548
02	413,8622	149,3925	511,6157	358,2901235
03	610,4887	559,8612	227,1606	465,8368178
04	934,4067	908,8827	963,635	935,6414571
05	721,7599	169,7609	112,5521	334,6909699
06	55,37104	302,0253	90,62427	149,3401924
07	437,3912	73,15811	109,7204	206,7565734
08	884,3097	134,8649	276,8777	432,0174377
09	270,4489	776,0497	807,9546	618,1510716
10	461,3184	61,78721	448,0059	323,7038246

#### Lampiran 4

Data sampel kadar IL-1 $\alpha$  pada lesi papulopustular

Kode Sampel	Hasil			Rata-rata (pg/ml)
	A	B	C	
11	36,63447	39,18206	35,99794	37,27148931
12	926,2452	831,8394	824,1288	860,7377948
13	645,4562	156,4616	461,5609	421,1595744
14	85,65393	167,7623	42,58249	98,66623817
15	396,913	272,2844	152,4832	273,8935157
16	801,8717	522,448	91,48955	471,9364265
17	309,2125	103,848	480,5258	297,8621143
18	215,8662	62,00134	253,7478	177,2051172
19	160,8882	200,7953	87,81389	149,832465
20	535,5377	532,8172	275,9585	448,1044574

## Lampiran 5

### Data sampel kadar IL-1 $\alpha$ pada lesi nodular

Kode Sampel	Hasil			Rata-rata (pg/ml)
	A	B	C	
21	165,765	170,8718	31,12269	122,5865065
22	157,3464	103,848	548,9211	270,0385234
23	294,8536	130,6958	125,2191	183,5894954
24	232,823	32,1818	506,7023	257,2356842
25	88,67833	208,4341	60,07481	119,0624177
26	582,0858	782,3591	37,69568	467,3802045
27	65,00077	350,7828	96,03655	170,6067013
28	61,35901	395,2463	442,9359	299,8470701

## Lampiran 6

### Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Komedonal	8	80.0%	2	20.0%	10	100.0%

### Descriptives

		Statistic	Std. Error
Komedonal	Mean	528.8549	79.08727
	95% Confidence Interval for Lower Bound	341.8432	
	Mean Upper Bound	715.8666	
	5% Trimmed Mean	517.6529	
	Median	448.9284	
	Variance	50038.368	
	Std. Deviation	223.69258	
	Minimum	323.70	
	Maximum	935.64	
	Range	611.94	
	Interquartile Range	385.83	
	Skewness	.999	.752
	Kurtosis	-.166	1.481

### Tests of Normality


	Kolmogorov-Smirnov <sup>a</sup>			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Komedonal	.236	8	.200*	.873	8	.161

a. Lilliefors Significance Correction


\*. This is a lower bound of the true significance.

## Lampiran 7



### Histogram



### Normal Q-Q Plot of Komedonal



**Detrended Normal Q-Q Plot of Komedonal**



```
EXAMINE VARIABLES=pustular /PLOT BOXPLOT HISTOGRAM NPLOT  
/COMPARE GROUP /STATISTICS DESCRIPTIVES /CINTERVAL 95  
/MISSING LISTWISE /NOTOTAL.
```



### Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Pustular	8	80.0%	2	20.0%	10	100.0%

### Descriptives

		Statistic	Std. Error
Pustular	Mean	292.3325	50.80717
	95% Confidence Interval for Mean	Lower Bound 172.1926	
		Upper Bound 412.4724	
	5% Trimmed Mean	293.1137	
	Median	285.8778	
	Variance	20650.951	
	Std. Deviation	143.70439	
	Minimum	98.67	
	Maximum	471.94	
	Range	373.27	
	Interquartile Range	284.69	
	Skewness	.001	.752
	Kurtosis	-1.765	1.481


### Tests of Normality

	Kolmogorov-Smirnov <sup>a</sup>			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Pustular	.190	8	.200*	.918	8	.413


a. Lilliefors Significance Correction

\*. This is a lower bound of the true significance.



**Histogram**



**Normal Q-Q Plot of Pustular**



**Detrended Normal Q-Q Plot of Pustular**



```
EXAMINE VARIABLES=nodular /PLOT BOXPLOT HISTOGRAM NPLOT  
/COMPARE GROUP /STATISTICS DESCRIPTIVES /CINTERVAL 95  
/MISSING LISTWISE /NOTOTAL.
```

### Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Nodular	8	80.0%	2	20.0%	10	100.0%

### Descriptives

		Statistic	Std. Error
Nodular	Mean	236.2933	40.70414
	95% Confidence Interval for Mean	Lower Bound 140.0433 Upper Bound 332.5433	
	5% Trimmed Mean	229.9680	
	Median	220.4126	
	Variance	13254.614	
	Std. Deviation	115.12868	
	Minimum	119.06	
	Maximum	467.38	
	Range	348.32	
	Interquartile Range	157.80	
	Skewness	1.140	.752
	Kurtosis	1.446	1.481

### Tests of Normality


	Kolmogorov-Smirnov <sup>a</sup>			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Nodular	.176	8	.200*	.896	8	.268

a. Lilliefors Significance Correction


\*. This is a lower bound of the true significance.

# Nodular


## Histogram



## Normal Q-Q Plot of Nodular



**Detrended Normal Q-Q Plot of Nodular**



**Frequency Table**

**JK**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	L	11	39.3	39.3	39.3
	P	17	60.7	60.7	100.0
Total		28	100.0	100.0	

**umur**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	12-17 tahun	16	57.1	57.1	57.1
	18-33 tahun	12	42.9	42.9	100.0
	Total	28	100.0	100.0	

**tipe AV**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	komedo	10	35.7	35.7	35.7
	pappust	10	35.7	35.7	71.4
	nodul	8	28.6	28.6	100.0
	Total	28	100.0	100.0	

**pncetjrwt**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	ya	21	75.0	75.0	75.0
	tdk	7	25.0	25.0	100.0
	Total	28	100.0	100.0	

**rokok**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	ya	4	14.3	14.3	14.3
	tdk	24	85.7	85.7	100.0
	Total	28	100.0	100.0	

**pedas**

		Frequency	Percent	Valid Percent	Cumulative Percent
--	--	-----------	---------	---------------	--------------------

Valid	ya	26	92.9	92.9	92.9
	tdk	2	7.1	7.1	100.0
	Total	28	100.0	100.0	

**mkn**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	kcng	12	42.9	42.9	42.9
	mnyk	13	46.4	46.4	89.3
	cklt	3	10.7	10.7	100.0
	Total	28	100.0	100.0	

**riwklg**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	ayah	7	25.0	25.0	25.0
	ibu	4	14.3	14.3	39.3
	saudara	10	35.7	35.7	75.0
	tdk	7	25.0	25.0	100.0
	Total	28	100.0	100.0	

**riw akne**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	< 1thn	1	3.6	3.6	3.6
	1-2 thn	15	53.6	53.6	57.1
	3-4 thn	10	35.7	35.7	92.9
	5-7 thn	2	7.1	7.1	100.0
	Total	28	100.0	100.0	



## T-Test

**Group Statistics**

JK	N	Mean	Std. Deviation	Std. Error Mean
IL-1 a L	11	3.446630862 00145E2	2.3040614655794 09E2	6.94700670476660 2E1
P	17	3.483914747 33821E2	2.3207833859508 67E2	5.62872649085530 8E1

**Independent Samples Test**

	Levene's Test for Equality of Variances	t-test for Equality of Means						
								95% Confidence Interval of the Difference
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference
IL-1 a Equal variances assumed	.083	.775	-.042	26	.967	-3.728388533676220E0	8.955509234408932E1	-1.8781
IL-1 a Equal variances not assumed			-.042	21.617	.967	-3.728388533676220E0	8.941110896579262E1	-1.8934

**Group Statistics**

umur	N	Mean	Std. Deviation	Std. Error Mean
------	---	------	----------------	-----------------

IL-1 a	12-17 tahun	16	4.064061737 44583E2	2.6626277384542 95E2	6.65656934613573 7E1
	18-33 tahun	12	2.676208532 30270E2	1.3389702348976 36E2	3.86527412777523 4E1

### Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means					95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
1 a	Equal variances assumed	4.111	.053	1.650	26	.111	1.387853205143 126E2	8.408897907966 810E1	-3.1163269247 3.406205144935 576E1	810
	Equal variances not assumed			1.803	23.221	.084	1.387853205143 126E2	7.697419018265 964E1	-2.9793484154 2.036420052104 871E1	740

```
GET FILE='C:\Documents and Settings\HP MINI\Desktop\spss 10-4-13\data 100413.sav'. T-TEST GROUPS=umur(1 2) /MISSING=ANALYSIS /VARIABLES=IL1a /CRITERIA=CI(.95).
```

### Group Statistics

pncetjr		N	Mean	Std. Deviation	Std. Error Mean
IL-1 a	ya	21	3.7641575 2968136E2	2.416680906229 835E2	5.273630087310 807E1
	tdk	7	2.5845974 3763672E2	1.589615360150 062E2	6.008181318864 909E1

**Independent Samples Test**

		Levene's Test for Equality of Variances		t-test for Equality of Means					
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	
IL-1 a	Equal variances assumed	.902	.351	1.200	26	.241	1.179560092044 645E2	9.832598619478 516E1	8.4
	Equal variances not assumed			1.475	15.964	.160	1.179560092044 645E2	7.994336561475 697E1	5.15

**Group Statistics**

rokok	N	Mean	Std. Deviation	Std. Error Mean
IL-1 a ya	4	2.581478638 40740E2	1.1517530884913 98E2	5.75876544245699 0E1
tdk	24	3.617232318 04733E2	2.3921530840913 68E2	4.88296203554079 3E1

**Independent Samples Test**

		Levene's Test for Equality of Variances		t-test for Equality of Means					
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lo
IL-1 a	Equal variances assumed	1.805	.191	-.840	26	.409	-1.035753679639 928E2	1.233326655946 942E2	3.57089

**Independent Samples Test**

		Levene's Test for Equality of Variances		t-test for Equality of Means					
				95% Confidence Interval of the Difference					
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower Bound
IL-1 a	Equal variances assumed	1.805	.191	-.840	26	.409	-1.233326655946 1.035753679639 928E2	942E2	3.5708
	Equal variances not assumed			-1.372	8.305	.206	-7.550277985728 1.035753679639 928E2	044E1	2.7657

**Group Statistics**

alkohol	N	Mean	Std. Deviation	Std. Error Mean
IL-1 a ya	2	1.448345594 94399E2	3.6447312475382 83E1	2.57721418073682 5E1
tdk	26	3.624723038 34145E2	2.2833609104187 63E2	4.47803916876933 1E1

**Independent Samples Test**

		Levene's Test for Equality of Variances		t-test for Equality of Means					
				95% Confidence Interval of the Difference					
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower Bound
IL-1 a	Equal variances assumed	2.039	.165	-1.324	26	.197	-1.643828216917 2.176377443397 460E2	047E2	5.555

### Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
										95%
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference		
IL-1 a	Equal variances assumed	2.039	.165	-1.324	26	.197	-2.176377443397460E2	1.643828216917047E2	5.555	
	Equal variances not assumed			-4.212	11.837	.001	-2.176377443397460E2	5.166707629663527E1	3.303	

### NPar Tests

[DataSet1] G:\DATA BARU\data 100413.sav

### Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
IL-1 a	28	3.46926750667020E2	2.271178879450503E2	3.727148931244E1	9.356414571435E2
mkn	28	1.68	.670	1	3

### Kruskal-Wallis Test

#### Ranks

	mkn	N	Mean Rank
IL-1 a	kcng	12	15.92

mnyk	13	12.31
cklt	3	18.33
Total	28	

**Test Statistics<sup>a,b</sup>**

	IL-1 a
Chi-Square	1.931
df	2
Asymp. Sig.	.381

a. Kruskal Wallis Test

b. Grouping Variable: mkn

**T-Test**

[DataSet4] C:\Documents and Settings\HP MINI\Desktop\DATA BARU\data 100413.sav

**Group Statistics**

type AV	N	Mean	Std. Deviation	Std. Error Mean
IL-1 a komedo	10	4.586933222 76416E2	2.4694159243930 94E2	7.80897881137232 9E1
pappust	10	3.236669192 76507E2	2.4103455174178 62E2	7.62218178301750 0E1

**Independent Samples Test**

		Levene's Test for Equality of Variances		t-test for Equality of Means				
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference
IL-1 a	Equal variances assumed	.015	.904	1.237	18	.232	1.350264029999 095E2	1.091227772785 434E2
	Equal variances not assumed			1.237	17.989	.232	1.350264029999 095E2	1.091227772785 434E2

## T-Test

[DataSet4] C:\Documents and Settings\HP MINI\Desktop\DATA BARU\data 100413.sav

### Group Statistics

tipe AV	N	Mean	Std. Deviation	Std. Error Mean
IL-1 a	10	4.586933222 76416E2	2.4694159243930 94E2	7.80897881137232 9E1
		nodul	8	2.362933253 93415E2

### Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means				
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference

IL-1 a	Equal variances assumed	3.348	.086	2.341	16	.032	2.223999968830011E2	9.49871112535920506E1	2.
	Equal variances not assumed			2.526					

### T-Test

#### Group Statistics

tipe AV		N	Mean	Std. Deviation	Std. Error Mean
IL-1 a	pappust	10	3.23666919276507E2	2.410345517417862E2	7.622181783017500E1
	nodul	8	2.36293325393415E2	1.151286842859032E2	4.070413668382361E1

#### Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means				
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference
IL-1 a	Equal variances assumed	2.795	.114	.939	16	.362	8.737359388309159E1	9.304695340561658E1
	Equal variances not assumed			1.011	13.458	.330	8.737359388309159E1	8.640944541259236E1

T-TEST PAIRS=IL1a WITH tipeAV (PAIRED) /CRITERIA=CI (.9500)  
/MISSING=ANALYSIS.



## NPar Tests

[DataSet1]

## Kruskal-Wallis Test

Ranks		
riw akne	N	Mean Rank
IL-1 a < 1thn	1	25.00
1-2 thn	15	16.13
3-4 thn	10	12.00
5-7 thn	2	9.50
Total	28	

Test Statistics <sup>a,b</sup>	
	IL-1 a
Chi-Square	3.883
df	3
Asymp. Sig.	.274

a. Kruskal Wallis Test

b. Grouping Variable: riw  
akne

```
NPAR TESTS /K-W=IL1a BY riwklg(1 2) /MISSING ANALYSIS.
```

## Oneway

### ANOVA

IL-1 a

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	947.448	2	473.724	.026	.974
Within Groups	182550.063	10	18255.006		
Total	183497.512	12			

## Lampiran 7

Rekomendasi persetujuan etik